At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1 enrolled
Drug / intervention
brinzolamide 1%/brimonidine 0.2% fixed combination +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 6-week, Double Masked, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Twice-daily Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to Travoprost 0.004% in Reducing Intraocular Pressure in Patients With Normal Tension Glaucoma
In Brief
A Phase 4 clinical trial evaluating brinzolamide 1%/brimonidine 0.2% fixed combination, Placebo, and 1 other intervention for Glaucoma. Completed, enrolled 1 participant across 1 site.
Detailed Summary
The purpose of this study was to determine the incremental intraocular pressure (IOP) lowering that is achieved when Simbrinza is used adjunctively to Travatan in patients with normal tension glaucoma that may benefit from further IOP lowering.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartSep 2017
Primary CompletionDec 2017
TodayJul 2026
First PostedMay 12, 2017
Enrollment StartSep 21, 2017
Primary CompletionDec 4, 2017
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 9.1 years ago
Interventions
brinzolamide 1%/brimonidine 0.2% fixed combinationdrug
One drop applied topically to the affected eye(s) in the morning and evening
Placebodrug
One drop applied topically to the affected eye(s) in the morning and evening
travoprost 0.004% ophthalmic solutiondrug
One drop applied topically to the affected eye(s) in the evening